Previous issue | Volume 94 | ESPE2021 | Next issue

59th Annual ESPE (ESPE 2021 Online)

22 Sep 2021 - 26 Sep 2021

Card image cap
The 59th ESPE Annual Meeting will now be held online in September 2021.

Free Communications

Bone and Mineral Metabolism

hrp0094fc6.1 | Bone and Mineral Metabolism | ESPE2021

Evaluation of the potential benefits of biphosphonate treatment on symptomatic vertebral fractures in children treated for acute lymphoblastic leukemia

Diaz Escagedo Patricia , Fiscaletti Melissa , Di Ioia Rose , Perrault Melissa , Olivier Patricia , Dubois Josee , Miron Marie-Claude , Laverdiere Caroline , Hoa Tran Thai , Alos Nathalie ,

Background and Aim: Vertebral fractures (VF) in children with acute lymphoblastic leukemia (ALL) are often symptomatic and impairing life quality. Prevalence of children with VF at ALL diagnosis has been reported as 16% with peak incidence occurring during the first year after diagnosis and a 6-year cumulative incidence of 32.5%. Moreover, only 15.8% of these patients will have vertebral reshaping 24 months after ALL diagnosis. Additionally, 23% of ALL survivo...

hrp0094fc6.2 | Bone and Mineral Metabolism | ESPE2021

Long-term effectiveness of PTH(1-34) infusion therapy for autosomal dominant hypocalcaemia type 1.

Sastre Ana , Valentino Kevin , Hannan Fadil M , Lines Kate E , Gluck Anna K , Stevenson Mark , Ryalls Michael , Gorrigan Rebecca , Pullen Debbie , Buck Jackie , Sankar Sailesh , Allgrove Jeremy , Thakker Rajesh V , Gevers Evelien F ,

Background: Patients with autosomal dominant hypocalcemia type 1 (ADH1), due to germline gain-of-function calcium-sensing receptor (CASR) mutations, have hypocalcemia and seizures, hyperphosphatemia, hypercalciuria and inappropriately low parathyroid hormone (PTH) concentrations. Treatment for ADH1 comprises calcium and vitamin D analogs, however, their use predisposes to nephrocalcinosis and renal impairment. In contrast, recombinant human PTH(1-34) may incre...

hrp0094fc6.3 | Bone and Mineral Metabolism | ESPE2021

Off-label use of cinacalcet in pediatric primary hyperparathyroidism: a French multi-centre experience

Bernardor Julie , Flammier Sacha , Salles Jean-Pierre , Castanet Mireille , Martinerie Laetitia , Lienhardt-Roussie Anne , Amouroux Cyril , Linglart Agnes , Bacchetta Justine ,

Background: For adult patients who do not meet indications to surgery, the calcimimetic cinacalcet is approved for primary hyperparathyroidism (HPT), decreasing calcium and parathyroid hormone (PTH) levels. This drug is largely used in adults, but may be a challenge in daily practice in children, because of the risk of hypocalcemia, increased QT interval and drug interactions. A few pediatric cases have highlighted its potential interest in children with HPT; ...

hrp0094fc6.4 | Bone and Mineral Metabolism | ESPE2021

Use of Aids, Assistive Devices and Adaptations (AADAs) by Individuals Aged <25 Years with Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Results from a Global Natural History Study (NHS)

Hsiao Edward C. , Pignolo Robert J. , Baujat Genevieve , Brown Matthew A. , De Cunto Carmen , Keen Richard , Mukaddam Mona Al , Marino Rose , Houchard Aude , Kaplan Frederick S. ,

Background: Individuals with the ultra-rare genetic disorder FOP experience progressive heterotopic ossification. Median age at diagnosis is 5 years; patients are supported by multiple specialties. Most patients become immobilised by the third decade of life, requiring lifelong assistance. We characterise AADA use as an indicator of disease severity in younger individuals with FOP enrolled in a 36-month, prospective, global NHS (NCT02322255).<p class="abst...

hrp0094fc6.5 | Bone and Mineral Metabolism | ESPE2021

What is the natural history of cervicomedullary compression without signal change in infants with achondroplasia? Investigating foramen magnum stenosis evolution.

Harvey Charlotte , Brett Connor , Cocca Alessandra , D’Arco Felice , Irving Melita , Thompson Dominic , Cheung Moira ,

Background: Foramen magnum stenosis (FMS) is a common, serious complication of achondroplasia in infancy. The Achondroplasia Foramen Magnum Score (AFMS; 1-4) was developed to facilitate early detection of stenosis and inform appropriate neurosurgical management. All infants have a baseline screening MRI, of which approximately half of cases demonstrate AFMS3 (craniovertebral junction (CVJ) narrowing with flattening of the cervical cord) or AFMS4 (CVJ narrowing...

hrp0094fc6.6 | Bone and Mineral Metabolism | ESPE2021

Use of lateral DEXA scanning for identifying and monitoring vertebral fractures in patients affected by Duchenne Muscular Dystrophy.

Turner Lucy , Lemon Jennifer , Landes Caren , Madhu Rajesh , Dharmaraj Poonam , Spinty Stefan ,

Introduction: International guidelines for management of Duchenne Muscular Dystrophy (DMD) advise active screening for vertebral fractures (VF), complications of which include pain, scoliosis and impact on ambulation. Vertebral fracture assessment (VFA) is a technique of visualising thoracic and lumbar vertebrae with a lateral view on dual energy X-ray absorptiometry (DEXA) to identify VF. This is at reduced cost and radiation exposure when compared to spinal ...